Merck Serono Initiates Phase III Trial Of Safinamide In Early Parkinson’s
Dosing and efficacy endpoint of the trial have been informed by earlier studies, including a failed Phase III.
Dosing and efficacy endpoint of the trial have been informed by earlier studies, including a failed Phase III.